WO1995003792B1 - Use of thiol compounds in the therapy of viral diseases - Google Patents
Use of thiol compounds in the therapy of viral diseasesInfo
- Publication number
- WO1995003792B1 WO1995003792B1 PCT/EP1994/002505 EP9402505W WO9503792B1 WO 1995003792 B1 WO1995003792 B1 WO 1995003792B1 EP 9402505 W EP9402505 W EP 9402505W WO 9503792 B1 WO9503792 B1 WO 9503792B1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- virus
- describes
- hepatitis
- treatment
- page
- Prior art date
Links
- -1 thiol compounds Chemical class 0.000 title claims abstract 6
- 208000001756 Virus Disease Diseases 0.000 title claims 3
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 241000700605 Viruses Species 0.000 claims abstract 15
- 201000010099 disease Diseases 0.000 claims abstract 6
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 4
- 229960004308 ACETYLCYSTEINE Drugs 0.000 claims 6
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims 6
- 241000700721 Hepatitis B virus Species 0.000 claims 3
- 206010019799 Hepatitis viral Diseases 0.000 claims 3
- 235000018417 cysteine Nutrition 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 201000001862 viral hepatitis Diseases 0.000 claims 3
- 206010047461 Viral infection Diseases 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 150000003573 thiols Chemical class 0.000 claims 2
- 230000017613 viral reproduction Effects 0.000 claims 2
- 206010059193 Acute hepatitis B Diseases 0.000 claims 1
- 208000000419 Chronic Hepatitis B Diseases 0.000 claims 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N Glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims 1
- 229960003180 Glutathione Drugs 0.000 claims 1
- 208000006454 Hepatitis Diseases 0.000 claims 1
- 208000002672 Hepatitis B Diseases 0.000 claims 1
- 108009000423 Hepatitis B infection Proteins 0.000 claims 1
- 241000724709 Hepatitis delta virus Species 0.000 claims 1
- 206010073071 Hepatocellular carcinoma Diseases 0.000 claims 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 1
- 241000700618 Vaccinia virus Species 0.000 claims 1
- 230000003466 anti-cipated Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000000875 corresponding Effects 0.000 claims 1
- 229920003013 deoxyribonucleic acid Polymers 0.000 claims 1
- 230000000249 desinfective Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 241001493065 dsRNA viruses Species 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 230000003902 lesions Effects 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 230000001878 mycolytic Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Abstract
A new use of thiol compounds is disclosed for preparing a pharmaceutical composition for treating virus-induced diseases. In particular, the use of thiol compounds is disclosed for preparing a pharmaceutical composition for treating virus-induced diseases, in which the used thiol compounds destroy the disulphide bridges in the virus proteins.
Claims
GEÄNDERTE ANSPRUCHE CHANGED CLAIMS
[beim Internationalen Büro am 20. Februar 1995 (20.02.95) eingegangen; ursprüngliche Ansprüche 1-11 durch geänderte Ansprüche 1-8 ersetzt (1 Seite)] 1 . Verwendung von DACEE oder einem Derivat davon für die Herstellung einer pharmazeutischen Zusammensetzung zur Behandlung Virus- induzierter Erkrankungen, [received at the International Bureau on 20 February 1995 (20.02.95); original claims 1-11 replaced by amended claims 1-8 (1 page)] 1. Use of DACEE or a derivative thereof for the manufacture of a pharmaceutical composition for the treatment of virus-induced diseases,
2. Verwendung nach Anspruch 1 , wobei das Virus ein DNA-oder RNA- Virus ist, 2. Use according to claim 1, wherein the virus is a DNA or RNA virus,
3. Verwendung nach Anspruch 1 oder 2, wobei das Virus ein Hepatitis- Virus ist. 3. Use according to claim 1 or 2, wherein the virus is a hepatitis virus.
4. Verwendung nach Anspruch 1 oder 2, wobei das Virus ein Hepadna- Virus ist. Use according to claim 1 or 2, wherein the virus is a hepadna virus.
5. Verwendung nach Anspruch 3 oder 4, wobei das Virus das Hepatitis-B- Virus ist. 5. Use according to claim 3 or 4, wherein the virus is the hepatitis B virus.
6. Verwendung nach Anspruch 3, wobei das Virus das Hepatitis-Delta- Virus ist. Use according to claim 3, wherein the virus is the hepatitis delta virus.
7. Verwendung nach Anspruch 1 oder 2, wobei das Virus ein Vaccinia- Virus ist. 7. Use according to claim 1 or 2, wherein the virus is a vaccinia virus.
8. Verwendung nach einem der Ansprüche 1 bis 6, wobei die Virus-induzierte Erkrankung eine chroniscne oder akute Hepatitis-B-Infektion oder ein hepatozelluläres Carcinom ist. IN ARTIKEL 19 GENANNTE ERKLÄRUNG Use according to any one of claims 1 to 6, wherein the virus-induced disease is a chronic or acute hepatitis B infection or a hepatocellular carcinoma. DECLARATION REFERRED TO IN ARTICLE 19
Als Stand der Technik werden die folgenden Druckschriften genannt: As prior art, the following publications are mentioned:
E1 WO-A-94/14473, E1 WO-A-94/14473,
E2 Chemical Abstracts, vol. 90, no. 9, abstract no. 66875 entsprechend E2 Chemical Abstracts, vol. 90, no. 9, abstract no. 66875 corresponding
der JP-A 53 1 18 516, JP-A 53 1 18 516,
E3 WO-A-90/08540, E3 WO-A-90/08540,
E4 US 4 708 965, E4 US 4,708,965,
E5 Laboratorio, Bd. 40, Nr. 239 (1965) S. 401 -423, E5 Laboratorio, Vol. 40, No. 239 (1965) p. 401-423,
E6 US 4 474 759, E6 US 4,474,759,
E7 US 4 378 351 , E7 US 4,378,351,
E8 De Flora S. et al., The American Jounai of Mediciπe, Bd. 91 Nr. 3C E8 De Flora S. et al., American Jounai of Medici, Vol. 91, No. 3C
( 1991 ), S. 122S - 130S, (1991), p. 122S-130S,
E9 FR-M-7 688, E9 FR-M-7 688,
E10 Bosio, G. und Marietti, G., Minerva Medica Bd. 69 (1978), S. 1495 - 1501 und E10 Bosio, G. and Marietti, G., Minerva Medica Vol. 69 (1978), pp. 1495-1501 and
E1 1 FR-M-4 619. E1 1 FR-M-4 619.
Der neue Anspruch 1 ist gegenüber E1 bis E 1 1 abgegrenzt. Er betrifft die Verwendung von DACEE oder einem Derivat davon für die Herstellung einer pharmazeutischen Zusammensetzung zur Behandlung Virus-induzierter Erkrankungen. The new claim 1 is delimited from E1 to E 1 1. It relates to the use of DACEE or a derivative thereof for the manufacture of a pharmaceutical composition for the treatment of virus-induced diseases.
E1 beschreibt die Verwendung von N-Acetylcystein (NAC) zur Herstellung eines Medikaments zur Behandlung viraler Hepatitis (vgl. E1 , z.B. Seite 5, Abs. 5 iVm. die Seiten 8 und 9 überbrückender Absatz). E1 describes the use of N-acetylcysteine (NAC) for the manufacture of a medicament for the treatment of viral hepatitis (see E1, e.g., page 5, para 5, supra, pages 8 and 9 for bridging paragraph).
E2 beschreibt die Verwendung von NAC als Desinfektionsmittel gegen Hepatitis-B- Viren, wobei das Mittel z.B. auf Virus-kontaminierte Finger und Kleidung aufgebracht wird (vgl. E2, Abstract von JP-A 531 18 516). E2 describes the use of NAC as a disinfectant against hepatitis B virus, the agent e.g. to virus-contaminated fingers and clothing is applied (see E2, Abstract of JP-A 531 18 516).
E3 beschreibt die Behandlung von HlV-infizierten Patienten mit NAC (vgl. E3, Anspruch 1 iVm. Anspruch 5). E4 beschreibt die Verabreichung von NAC an Personen, die an Herpes-Läsionen leiden (vgl. E4, Anspruch 1 ). E3 describes the treatment of HIV-infected patients with NAC (compare E3, claim 1 in conjunction with claim 5). E4 describes the administration of NAC to persons suffering from herpes lesions (see E4, claim 1).
E5 beschreibt die Wirkung von Cystein auf Viren (vgl. E5, Titel iVm. die Seiten 401 und 402 überbrückender Absatz). E5 describes the effect of cysteine on viruses (see E5, title in conjunction with the paragraphs 401 and 402 bridging paragraph).
E6 beschreibt die Behandlung von Patienten, die an einer viralen Infektion leiden, mit Cystein-Dinatriumsalz (vgl. E6, Anspruch 1 iVm. Spalte 1 , Zeilen 9- 14) . E6 describes the treatment of patients suffering from a viral infection with cysteine disodium salt (compare E6, claim 1 in conjunction with column 1, lines 9-14).
E7 beschreibt die Behandlung von Patienten, die an einer viralen Infektion leiden, mit Cystein-Dinatriumsalz (vgl. E7, Anspruch 1 iVm. Spalte 1 , Zeilen 1 8-23) . E7 describes the treatment of patients suffering from a viral infection with cysteine disodium salt (compare E7, claim 1 in conjunction with column 1, lines 1 8-23).
E8 beschreibt, daß die Verabreichung von Thiolen Mutationen und Krebs vorbeugt. Dies ist insbesondere bei Erkrankungen nützlich, die von einer GSH-Verminderung begleitet sind, die z.B. durch Hepatiτis-B-Viren verursacht wird (vgl. E8, Abstract, letzter Satz). E8 describes that the administration of thiols prevents mutations and cancer. This is especially useful in diseases accompanied by a reduction in GSH, e.g. caused by Hepatitis B viruses (see E8, abstract, last sentence).
E9 beschreibt die Behandlung von Patienten, die unter einer viralen Hepatrtis leiden, mit einer NAC-enthaltenden Zusammensetzung (vgl. E9, Beispiel 1 auf Seite 4) . E9 describes the treatment of patients suffering from viral hepatitis with an NAC-containing composition (see E9, Example 1 on page 4).
E10 beschreibt die Behandlung viraler Hepatitis mit dem Thiol σ-MPG (vgl. E10, Seite 1496, linke Spalte, Abs. 5 iVm. Seite 1500, rechte Spalte, Abs. 8). E10 describes the treatment of viral hepatitis with the thiol σ-MPG (compare E10, page 1496, left column, section 5 in conjunction with page 1500, right column, section 8).
E1 1 beschreibt die Verwendung von DACEE als Mykolyticυm (vgl. EU : Beispiel 2 auf Seite 2 iVm. Seite 2, rechte Spalte unter der Überschrift "Resumee"). E1 1 describes the use of DACEE as mycolytic (compare EU: Example 2 on page 2 in conjunction with page 2, right column under the heading "Resumee").
Somit wird der Gegenstand des neuen Anspruchs 1 durch keine der Druckschriften E1 - E1 1 vorweggenommen. Auch wird er nicht durch eine oder eine Kombination aus diesen nahegelegt. Der Gegenstand des neuen Anspruchs 1 ist daher neu und beruht auf erfinderischer Tätigkeit gegenüber dem zitierten Stand der Technik. Thus, the subject matter of the new claim 1 by any of the documents E1 - E1 1 anticipated. Nor is he suggested by one or a combination of these. The subject matter of new claim 1 is therefore novel and is based on inventive step in relation to the cited prior art.
Priority Applications (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/617,820 US6045832A (en) | 1993-07-29 | 1994-07-28 | Use of DACEE and Derivatives for treating viral diseases |
| EP94925410A EP0716601B1 (en) | 1993-07-29 | 1994-07-28 | Use of n,s-diacetylcysteine-ethylester (dacee) for the manufacture of a medicament for the treatment of viral diseases |
| JP7505566A JPH09500887A (en) | 1993-07-29 | 1994-07-28 | Use of thiol compounds to treat viral diseases |
| DE59409413T DE59409413D1 (en) | 1993-07-29 | 1994-07-28 | USE OF N, S-DIACETYLCYSTEIN ETHYLESTER (DACEE) FOR PRODUCING A MEDICINE FOR TREATING VIRAL DISEASES |
| AT94925410T ATE194076T1 (en) | 1993-07-29 | 1994-07-28 | USE OF N,S-DIACETYLCYSTEINE ETHYL ESTER (DACEE) FOR PRODUCING A MEDICATION FOR THE TREATMENT OF VIRAL DISEASES |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE4325547A DE4325547C2 (en) | 1993-07-29 | 1993-07-29 | Use of thiol compounds for the therapy of hepatitis-virus-induced diseases |
| DEP4325547.7 | 1993-07-29 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO1995003792A1 WO1995003792A1 (en) | 1995-02-09 |
| WO1995003792B1 true WO1995003792B1 (en) | 1995-03-16 |
Family
ID=6494044
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP1994/002505 WO1995003792A1 (en) | 1993-07-29 | 1994-07-28 | Use of thiol compounds in the therapy of viral diseases |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US6045832A (en) |
| EP (1) | EP0716601B1 (en) |
| JP (1) | JPH09500887A (en) |
| AT (1) | ATE194076T1 (en) |
| DE (2) | DE4325547C2 (en) |
| WO (1) | WO1995003792A1 (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4406261C2 (en) * | 1993-08-31 | 1996-07-04 | Deutsches Krebsforsch | Use of thiol compounds to reduce body fat |
| US6013632A (en) * | 1997-01-13 | 2000-01-11 | Emory University | Compounds and their combinations for the treatment of influenza infection |
| DE19735120A1 (en) * | 1997-08-13 | 1999-02-18 | Peter Hans Prof D Hofschneider | Use of thiol-compositions for inactivating virus in cell-free environments |
| CN1549709A (en) * | 2001-07-16 | 2004-11-24 | ����ɯ�ס����ڵ��ɿ� | Application of one antiviral compound in production of preparation for treating respiratory virus infection |
| AT411149B (en) * | 2001-07-16 | 2003-10-27 | Gaudernak Elisabeth | Treatment or prevention of RNA viral infections of the respiratory tract, using N,N-dialkyl- or N-heterocyclyl-dithiocarbamic acid compounds, also useful as antiviral disinfectants |
| WO2008135984A1 (en) * | 2007-05-03 | 2008-11-13 | Ramot At Tel-Aviv University Ltd. | Composition comprising s-allylmercapto-n-acetylcysteine (assnac) for up-regulation of cellular glutathione level |
| EP3235815A1 (en) | 2016-04-19 | 2017-10-25 | Philipps-Universität Marburg | Agents against parasitic helminths |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR4619M (en) * | 1965-02-01 | 1966-11-28 | ||
| FR7688M (en) * | 1968-09-17 | 1970-02-16 | ||
| US3786143A (en) * | 1968-12-23 | 1974-01-15 | Haessle Ab | Method for treating virus infection affecting the brain |
| JPS53118516A (en) * | 1977-03-24 | 1978-10-17 | Ajinomoto Co Inc | Inactivation disinfectant of hepatitis-b virus |
| US4452781A (en) * | 1980-07-11 | 1984-06-05 | Vojislav Petrovich | Method of treating bacterial viral or parasitic diseases |
| US4378351A (en) * | 1980-07-11 | 1983-03-29 | Vojislav Petrovich | Methods of treating bacterial, viral or parasitic diseases |
| US4469678A (en) * | 1982-07-22 | 1984-09-04 | Vojislav Petrovich | Method of treating bacterial, viral or parasitic diseases |
| US4474759A (en) * | 1982-07-22 | 1984-10-02 | Vojislav Petrovich | Method of treating bacterial, viral or parasitic diseases |
| JPS59110618A (en) * | 1982-12-16 | 1984-06-26 | Yoshitomi Pharmaceut Ind Ltd | Antitumor agent |
| US4708965A (en) * | 1985-09-16 | 1987-11-24 | Morgan Lee R | Method of treating herpes virus infections with N,N'-diacetylcystine and derivatives |
| CA1339070C (en) * | 1989-01-26 | 1997-07-29 | Wulf Droge | Treatment of diseases associated with cysteine deficiency |
| CH683485A5 (en) * | 1990-11-20 | 1994-03-31 | Pasteur Merieux Serums Vacc | infusion solutions, preservation and organ perfusion. |
| GB9226729D0 (en) * | 1992-12-22 | 1993-02-17 | Wellcome Found | Therapeutic combination |
-
1993
- 1993-07-29 DE DE4325547A patent/DE4325547C2/en not_active Expired - Fee Related
-
1994
- 1994-07-28 DE DE59409413T patent/DE59409413D1/en not_active Expired - Fee Related
- 1994-07-28 WO PCT/EP1994/002505 patent/WO1995003792A1/en active IP Right Grant
- 1994-07-28 US US08/617,820 patent/US6045832A/en not_active Expired - Fee Related
- 1994-07-28 AT AT94925410T patent/ATE194076T1/en not_active IP Right Cessation
- 1994-07-28 EP EP94925410A patent/EP0716601B1/en not_active Expired - Lifetime
- 1994-07-28 JP JP7505566A patent/JPH09500887A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69127020T2 (en) | Milk protein hydrolyzates and compositions for use as hair and skin treatments | |
| DE60223340T2 (en) | SERPINE DRUGS FOR THE TREATMENT OF HIV INFECTION AND METHOD FOR THEIR USE | |
| BR9813373A (en) | Compound, process for preparing it, pharmaceutical composition, process for preparing it, use of a compound, and, processes for effecting immunosuppression and for treating or reducing the risk of reversibly obstructive airway disease in a patient | |
| DE69317992T2 (en) | Aminoketone derivatives | |
| KR100479669B1 (en) | Use of L-acetylcarnitine, L-isovalerylcarnitine, L-propionylcarnitine useful for increasing levels of IGF-1 | |
| WO2007138116A2 (en) | Pharmaceutical composition for the treatment of viral infections and/or tumor diseases by inhibiting protein folding and protein breakdown | |
| CA2155933A1 (en) | Pulmonary Administration of sCR1 and Other Complement Inhibitory Proteins | |
| ATE241365T1 (en) | PREPARATIONS CONTAINING SACCHARIDE FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND OTHER AMYLOIDOSES | |
| WO2005037257A2 (en) | Novel alanyl-amino peptidase inhibitors for functionally influencing different cells and treating immunological, inflammatory, neuronal, and other diseases | |
| WO1995003792B1 (en) | Use of thiol compounds in the therapy of viral diseases | |
| DE68929388T2 (en) | Anticoagulant compound isolated from urine | |
| DE68911891D1 (en) | Use of acetyl-L-carnitine for the treatment of cataracts, as well as pharmaceutical compositions for such a treatment. | |
| DE59309044D1 (en) | PARATHORMON FRAGMENTS, THEIR PRODUCTION AND MEDICINAL PRODUCTS CONTAINING THEM | |
| DE59610205D1 (en) | APPLICATION OF A MEDICINE AND USE OF A SUBSTANCE MIXTURE FOR PRODUCING A MEDICINAL PRODUCT | |
| WO2012104355A1 (en) | Antiviral agent containing recombinant mistletoe lectins | |
| PT81387A (en) | Process for preparing pharmaceutical compositions containing 1--beta-d-ribofuranosyl-1,2,4-triazole-3-carboxamide useful for treating human viral disfases | |
| KR970005283A (en) | Use of sertraline to treat patients after myocardial infarction | |
| CA2166318A1 (en) | Pharmaceutical compositions and their use, namely for the treatment of neurodegenerative diseases | |
| ATE194076T1 (en) | USE OF N,S-DIACETYLCYSTEINE ETHYL ESTER (DACEE) FOR PRODUCING A MEDICATION FOR THE TREATMENT OF VIRAL DISEASES | |
| WO2000004884A9 (en) | Pharmaceutical preparations for the topical treatment of mucocutaneous herpes infections and herpetic keratitis of the eye | |
| DE60121913T2 (en) | ALANIN- AND GLYCIN-CONTAINING DRUGS AGAINST HEPATITIS | |
| DE69113437T2 (en) | Therapeutic agents for diabetic gangrene. | |
| DE69424415T2 (en) | USE OF EFAROXAN AND DERIVATIVES FOR PRODUCING A MEDICINAL PRODUCT FOR TREATING PARKINSON'S DISEASE | |
| DE1667890A1 (en) | Cosmetic and pharmaceutical preparations for the treatment of the skin | |
| EP0969017A1 (en) | Modified C1-esterase inhibitor for blocking infectivity of HIV |